A closer look at NewAmsterdam Pharma Company NV’s (NAMS) current quarter earnings projections

Cameron Mitchell

NewAmsterdam Pharma Company NV (NAMS)’s stock has witnessed a price hike of 1.58% from the previous close with its current price standing at $24.5. Its current price is -10.42% under its 52-week high of $27.35 and 74.25% more than its 52-week low of $14.06.

Additionally, it is important to take into account NAMS stock ratios, including its price-to-sales ratio, which is 43.11 for the last tewlve months.NAMS’s price to book ratio for the most recent quarter was 3.54, resulting in an 3.73 price to cash per share for the period.

How does NewAmsterdam Pharma Company NV (NAMS) stock rate among analysts? Buy, sell, or hold?

The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1.

NewAmsterdam Pharma Company NV (NAMS): Earnings History

If we examine NewAmsterdam Pharma Company NV’s recent earnings history, in the last quarter ended on 6/30/2025, it posted adjusted earnings per share of -$0.13, slashing the consensus of -$0.43. In other words, it beat the consensus by $0.3, resulting in a 69.85% surprise. In the 3 months period before the previous quarter which was closed on 6/30/2025, the stock recorded adjusted earnings per share of -$0.13 in contrast with the Outlook of -$0.43. That was a difference of $0.3 and a surprise of 69.85%.

NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Ownership Details

I will give a breakdown of the key shareholders in NewAmsterdam Pharma Company NV (NAMS). Recent figures show that the company’s insiders hold 0.38% of shares. A total of 195 institutional investors hold shares in the company, making 106.99% of its stock and 107.41% of its float.

Jun 30, 2025, it was reported that the Company’s largest institutional holder is SmallCap World Fund Inc holding total of 8.4 shares that make 7.45% of the company’s total number of shares and are currently priced at 205.03 million.

The securities firm VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund holds 2.16 shares of NAMS, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 1.91%, and the holding percentage of shares is valued at 52.66 million.

An overview of NewAmsterdam Pharma Company NV’s technicals

Leave a Comment

US Post News
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.